Treatment of chronic cough: P2X3 receptor antagonists and beyond
- PMID: 35263649
- DOI: 10.1016/j.pharmthera.2022.108166
Treatment of chronic cough: P2X3 receptor antagonists and beyond
Abstract
For years chronic cough (CC) has presented an enormous physical, psychological, and social burden on those who experience it, with no approved pharmacological therapies to assuage their symptoms. With our improved understanding of the pathophysiological mechanisms of CC, primarily the recognition of neuronal dysregulation in its aetiology, there appears to be a new hope for such patients. In this review we discuss the multitude of proposed pharmacological targets in CC, including the promising results produced by the antagonism of P2X3 receptors. We also assess the evidence of other peripherally acting pharmacolgical agents still in development.
Keywords: ATP; Cough; Gefapixant; P2X3 receptors; Purinergic receptors.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest DS reports no conflict of interest. MZ reports no conflict of interest. AM reports fees for advisory boards and grant funding from Merck, Bayer, NeRRi, Shionogi, Bellus and Nocion.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical